Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals
Portfolio Pulse from
Neumora Therapeutics' stock plummeted 80% after its depression drug failed to meet goals in a late-stage study.
January 02, 2025 | 4:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Neumora Therapeutics' stock fell 80% after its depression drug failed in a late-stage study, reaching an all-time low.
The failure of the depression drug in a late-stage study is a significant setback for Neumora Therapeutics, leading to an 80% drop in stock price. This indicates a loss of investor confidence and potential financial challenges ahead.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100